The IBD SmartSelect Composite Rating for Rigel Pharmaceuticals increased from 88 to 97 Tuesday.
Discover The 3 Keys To Successful Stock Investing
The new rating is a sign the stock is outpacing 97% of all stocks when it comes to the most important stock-picking criteria. The top-performing stocks tend to have a 95 or better grade as they start a significant move so be sure to keep that in mind when looking for the best stocks to buy and watch.
Rigel Pharmaceuticals is currently forming a consolidation, with a 25.42 buy point. See if the stock can break out in volume at least 40% above average. Be aware that it is a thinly traded stock, with average daily dollar volume under $8 million. Less liquid stocks are more prone to volatile action since it takes fewer shares bought or sold to move the share price.
The stock has an 80 EPS Rating, meaning its recent quarterly and annual earnings growth is outpacing 80% of all stocks.
Its Accumulation/Distribution Rating of B shows moderate buying by institutional investors over the last 13 weeks.
In Q1, the company posted 0% earnings-per-share growth. Top line growth increased 81%, up from 61% in the prior report. That marks one quarter of rising revenue increases. The company's next quarterly report is expected on or around Aug. 5.
Rigel Pharmaceuticals earns the No. 5 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
